| 영문 | pelvic inflammatory disease | 한글 | 골반염질환 |
|---|---|---|---|
| 설명 | 골반주위의 장기에 발생하는 염증을 말함. 주로 여성에서 발생하며 원인은 임균(gonococcus)과 비임균에 의한 감염(non-gonorrheal infection)에 의한다. 증상은 초기에는 질분비물, 하복부동통, 여성의 생식기부위에 발생하는 압통, 월경통, 월경량의 증가 등이다. 일찍 치료해야 하며, 계속적으로 병이 지속시 여성의 불임의 원인이 된다. 후진국에서는 가장 많은 여성불임의 원인이기도 함. 치료는 항생제의 투여이다. |
||
| 영문 | inflammatory bowel disease | 한글 | 염증성창자병 |
|---|---|---|---|
| 설명 | 위장관을 침범하는 정확한 원인이 밝혀지지 않은 만성적인 염증성 질환을 말한다. 크게 ‘궤양성 대장염’(ulcerative colitis)과 ‘크론병’(Crohn's disease)의 두 종류로 구분된다. 백인, 유태인에 많고 흑인이나 동양인에는 드물지만 동양인에서 점차 증가추세에 있다. 호발연령은 15~35세 사이이다. 증상은 ‘궤양성 대장염’의 경우, 설사(혈변 및 점액변), 뒤무직, 복통, 복부압통, 체중감소 등이 주로 나타나며 ‘크론병’에서는 설사와 체중감소, 우하복부 종류, 항문주위 이상, 복부압통 등이 나타난다. 진단은 병력과 방사선학적 검사, 직장경 및 대장 내시경검사, 직장 및 대장의 조직검사로 하며 치료는 내과적인 치료가 원칙이나 내과적 치료에 듣지 않거나 합병증이 생길 경우에는 외과적 치료를 시행한다. ‘궤양성 대장염’의 경우에는 ‘대장암’을 예방하기 위해서 외과적 치료를 하기도 한다. ‘궤양성 대장염’과 ‘크론 병’외에 염증성 창자병에 속하는 ‘베체트 병’은 재발성 구강내 궤양, 피부 병변, 안구부 염증, 외음부 궤양, 관절염 증상, 위창자관 증상(복통, 장출혈), 부고환염 등의 증상을 나타내는데 진단과 치료는 ‘궤양성 대장염’, ‘크론 병’과 비슷하다. |
||
| 영문 | anti-inflammatory agent | 한글 | 항염증제, 소염제, 염증약 |
|---|---|---|---|
| 설명 | 국소에 작용하여 염증을 치료하고 방지하는 약. 염증을 가라앉히는 약을 말한다. 조직을 긴축-치밀하게 하여 장액과 점액의 분비를 줄이고, 표면에 있는 작은 혈관에 빈혈을 일으켜 충혈되는 것을 방지함으로써 염증적 병변을 제거하여 모든 증세를 없앤다. 대부분의 수렴제-완화제-진양제가 이에 속한다. 중요한 성분으로는 알루미늄-비스무트-아연-납화합물(병반-페르마톨-아연화-연당 등) 등이 있다. 작용에 따라 항염증진통제와 항염증효소제로 나뉜다. |
||
| PAIN | pyoderma gangrenosum, aphthous stomatitis, inflammatory eye disease, erythema nodosum [disorders ass... |
|---|---|
| MIP | macrophage inflammatory protein; major intrinsic protein; maximum inspiratory pressure; maximum inte... |
| MIPA | macrophage inflammatory protein alpha |
| MIPB | macrophage inflammatory protein beta |
| MAF | macrophage activation factor; macrophage agglutinating factor; maximum atrial fragmentation; minimum... |
| MIP | Macrophage Inflammatory Protein |
|---|---|
| MIP-1 | Macrophage inflammatory proteins-1 |
| MIP-1 alpha | Macrophage Inflammatory Protein 1 alpha |
| MIP-2 | Macrophage inflammatory protein 2 |
| MIP-1beta | Macrophage inflammatory protein-1beta |
| inflammatory macrophage | A macrophage found at sites of inflammation. (05 Mar 2000) |
|---|
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
|---|---|
| activated macrophage | A mature macrophage, in an active metabolic state, that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. Synonym: armed macrophage. (05 Mar 2000) |
| alveolar macrophage | Macrophage found in lung and that can be obtained by lung lavage, responsible for clearance of inhaled particles and lung surfactant. Metabolism slightly different from peritoneal macrophages (more oxidative metabolism), often have multivesicular bodies that may represent residual undigested lung surfactant. (18 Nov 1997) |
| alveolar macrophage elastase | <enzyme> Metalloproteinase found in human alveolar macrophages Registry number: EC 3.4.24.- Synonym: elastase, alveolar macrophage, metalloproteinase elastase, human macrophage metalloelastase, mmp12 gene product, mmp-12 gene product, mme gene product, macrophage metalloelastase (26 Jun 1999) |
| armed macrophage | A mature macrophage, in an active metabolic state, that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. Synonym: armed macrophage. (05 Mar 2000) |
| associated macrophage | A mature macrophage in an active metabolic state that is cytotoxic to tumour/target cells, usually following exposure to certain cytokines. (05 Mar 2000) |
| macrophage | Relatively long lived phagocytic cell of mammalian tissues, derived from blood monocyte. Macrophages from different sites have distinctly different properties. Main types are peritoneal and alveolar macrophages, tissue macrophages (histiocytes), Kupffer cells of the liver and osteoclasts. In response to foreign materials may become stimulated or activated. Macrophages play an important role in killing of some bacteria, protozoa and tumour cells, release substances that stimulate other cells of the immune system and are involved in antigen presentation. May further differentiate within chronic inflammatory lesions to epithelioid cells or may fuse to form foreign body giant cells or Langhans giant cells. (18 Nov 1997) |
| macrophage-1 antigen | An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| macrophage-activating factor | An agent that stimulates macrophages to attack and ingest cancer cells. They are secreted by stimulated lymphocytes that prime macrophages to become non-specifically cytotoxic to tumours. They also modulate the expression of macrophage cell surface ia antigens. One maf is interferon-gamma (interferon type II). Other factors antigenically distinct from ifn-gamma have also been identified. (12 Dec 1998) |
| macrophage activation | The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants. (12 Dec 1998) |
| macrophage colony-stimulating factor | <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages. A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes). The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene. See: colony-stimulating factors. Chemical name: Colony-stimulating factor 1 Acronym: M-CSF (12 Dec 1998) |
| macrophage inhibition factor | <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion. (18 Nov 1997) |
| macrophage migration inhibition test | A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced. Synonym: macrophage migration inhibition test, migration inhibition test. (05 Mar 2000) |
| macrophage migration-inhibitory factors | Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell. (12 Dec 1998) |
| receptors, granulocyte-macrophage colony-stimulating factor | Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|